Maria Beumont

Beerse, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications

Pharmacokinetics and safety of TBAJ-587, a novel antimycobacterial diarylquinoline, in healthy participants.

Pharmacokinetics and safety of TBAJ-587, a novel antimycobacterial diarylquinoline, in healthy participants.

Journal: Antimicrobial agents and chemotherapy
Published: July 28, 2026

Safety evaluation of pretomanid, an anti-tuberculosis drug, for the treatment of pregnant and lactating women.

Safety evaluation of pretomanid, an anti-tuberculosis drug, for the treatment of pregnant and lactating women.

Journal: Antimicrobial agents and chemotherapy
Published: July 10, 2026

Preserved Spermatogenesis and Hormonal Function in Men Receiving a Pretomanid Regimen (BPaMZ) for Pulmonary Drug-Resistant Tuberculosis.

Preserved Spermatogenesis and Hormonal Function in Men Receiving a Pretomanid Regimen (BPaMZ) for Pulmonary Drug-Resistant Tuberculosis.

Journal: Clinical pharmacology and therapeutics
Published: November 25, 2025

Protocol for a phase 2, partially blinded, randomized trial assessing the safety and efficacy of sorfequiline or bedaquiline in combination with pretomanid and linezolid in adult participants with newly diagnosed, drug-sensitive, smear-positive pulmonary tuberculosis (NC-009).

Protocol for a phase 2, partially blinded, randomized trial assessing the safety and efficacy of sorfequiline or bedaquiline in combination with pretomanid and linezolid in adult participants with newly diagnosed, drug-sensitive, smear-positive pulmonary tuberculosis (NC-009).

Journal: Trials
Published: August 05, 2025

Hepatic safety of pretomanid- and pyrazinamide-containing regimens in TB Alliance clinical trials.

Hepatic safety of pretomanid- and pyrazinamide-containing regimens in TB Alliance clinical trials.

Journal: IJTLD open
Published: March 17, 2025

Pharmacokinetics, tolerability, and safety of TBI-223, a novel oxazolidinone, in healthy participants.

Pharmacokinetics, tolerability, and safety of TBI-223, a novel oxazolidinone, in healthy participants.

Journal: Antimicrobial agents and chemotherapy
Published: March 11, 2025

Optimal dosing and duration of linezolid for the treatment of multidrug-resistant and rifampicin-resistant tuberculosis: an individual patient data meta-analysis.

Optimal dosing and duration of linezolid for the treatment of multidrug-resistant and rifampicin-resistant tuberculosis: an individual patient data meta-analysis.

Journal: The European respiratory journal
Published: December 07, 2024

Predictable excess hepatotoxicity in the SimpliciTB trial - Authors' reply.

Predictable excess hepatotoxicity in the SimpliciTB trial - Authors' reply.

Journal: The Lancet. Infectious diseases
Published: October 14, 2024

Pharmacokinetics and safety of TBAJ-876, a novel antimycobacterial diarylquinoline, in healthy subjects.

Pharmacokinetics and safety of TBAJ-876, a novel antimycobacterial diarylquinoline, in healthy subjects.

Journal: Antimicrobial agents and chemotherapy
Published: August 28, 2024

JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2.

JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2.

Journal: Journal of hepatology
Published: August 23, 2023

Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.

Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.

Journal: The lancet. Gastroenterology & hepatology
Published: January 19, 2023

Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection.

Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection.

Journal: Gut
Published: June 10, 2022
Showing 1-12 of 37

Last Updated: 09/26/2026